check_circleStudy Completed

Hypertension

Bayer Identifier:

11819

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

2004-004125-10

EU CT Number:

Not Available
Study on safety, tolerability and pharmacokinetics of one tablet Adalat OROS 30 or of one tablet Nifedipine Sandoz retard 30 after an overnight fasting or immediately after an American breakfast in healthy male volunteers

Trial purpose

Please see attached Study Results Summary below

Key Participants Requirements

Sex

N/A

Age

18 - 40 Years

Trial summary

Enrollment Goal
28
Trial Dates
January 2005 - February 2005
Phase
Phase 1
Could I Receive a placebo
N/A
Products
Adalat Oros (Nifedipine, BAYA1040)
Accepts Healthy Volunteer
N/A

Where to participate

StatusInstitutionLocation
Completed
SocraTec R&D Clinical WardErfurt, 99084, Germany

Trial design

Randomized, non-blind, 4-fold crossover study on safety, tolerability and pharmacokinetics of nifedipine after single oral doses of one tablet Adalat OROS 30 or of one tablet Nifedipine Sandoz retard 30 after an overnight fasting or immediately after an American breakfast in healthy male volunteers.
Trial Type
Interventional
Intervention Type
N/A
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A

Additional Information

Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.